Dong Sung Bio Pharm.Co.,Ltd. Stock: price and insider trades · South Korea
동성제약
No insider purchase over the last 90 days. The latest, by 아이비케이금융그룹-유암코 중기도약 펀드, was filed 15 Apr 2026.
Who traded when
BuySaleSince the insiders bought
- +22.9%Entry ₩973 · Close 30 Oct 2026 ₩1,196
- +22.9%Entry ₩973 · Close 30 Oct 2026 ₩1,196
- +22.9%Entry ₩973 · Close 30 Oct 2026 ₩1,196
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 8,500,000 shares@ ₩1,000.005.11% mcap100.0% of flowShareKRXDART:20260415000150Canonical exit: 8 Jul 2026 (T+90)
- 10,000,000 shares@ ₩1,000.006.01% mcap100.0% of flowShareKRXDART:20260415000146Canonical exit: 8 Jul 2026 (T+90)
- 31,500,000 shares@ ₩1,000.0018.92% mcap21.4% of flowShareKRXDART:20260415000145Canonical exit: 8 Jul 2026 (T+90)
- 50,000,000 shares28.92% mcap32.7% of flowKRXDART:20260415000133Canonical exit: 8 Jul 2026 (T+90)
- 7,056,567 shares4.12% mcap100.0% of flowKRXDART:20260410003004
- 8,500,000 shares@ ₩1,000.004.64% mcap100.0% of flowShareKRXDART:20260406003088Canonical exit: 29 Jun 2026 (T+90)
- 31,500,000 shares@ ₩1,000.0017.21% mcap100.0% of flowShareKRXDART:20260406003057Canonical exit: 29 Jun 2026 (T+90)
- 30,000,000 shares@ ₩1,000.0016.39% mcap100.0% of flowShareKRXDART:20260406003134Canonical exit: 29 Jun 2026 (T+90)
- 70,000,000 shares40.49% mcap45.8% of flowKRXDART:20260406003017Canonical exit: 29 Jun 2026 (T+90)
- ●Executives0DART
- ●Executives0DART
- 697,861 sharesKRXDART:20250701000443
- 300,000 shares@ ₩989.00100.0% of flowShareKRXDART:20250701000444
- 2,210,433 sharesKRXDART:20250610000414Canonical exit: 11 Aug 2025 (T+90)
- 2,819,673 sharesShareKRXDART:20250428000614Canonical exit: 27 Jul 2025 (T+90)
- 0KRXDART:20241220000607
- ●Executives0DART
- 1,259 sharesKRXDART:20240920000287Canonical exit: 18 Dec 2024 (T+90)
- 990 sharesKRXDART:20240620000257Canonical exit: 18 Sept 2024 (T+90)
- 990 sharesKRXDART:20240508000338Canonical exit: 5 Aug 2024 (T+90)
- 990 sharesKRXDART:20231228000592Canonical exit: 26 Mar 2024 (T+90)
- 990 sharesKRXDART:20231130001477Canonical exit: 25 Feb 2024 (T+90)
- 990 sharesKRXDART:20230830001166Canonical exit: 26 Nov 2023 (T+90)
- 990 sharesKRXDART:20230531002546Canonical exit: 27 Aug 2023 (T+90)
- 990 sharesKRXDART:20230524000491Canonical exit: 2 Aug 2023 (T+90)
25 of 47 declarations
About Dong Sung Bio Pharm.Co.,Ltd.
Between March 31 and April 9, 2026, 3 filers bought shares of 동성제약 (Dong Sung Bio Pharm.Co.,Ltd.) for EUR 136,270,241 in total. The three largest purchases in the record come from the same fund, 유암코제약산업제1호기업재무안정사모투자: EUR 39,095,140 on March 31, EUR 27,925,100 and EUR 18,270,000 on April 9.
The company, a South Korean health care name worth KRW 123.3 billion with insiders at 75.7%, has 47 filings dated March 9, 2021 to April 15, 2026. Those split into 34 purchases, 3 sales and 10 other filings. Eight purchases come with an amount, and their median is EUR 17,681,250. The largest sale is by 상상인저축은행: EUR 3,982,303 on April 7, 2026.
Read moreShow less
이양구 is the most present filer, with 27 filings including 23 purchases. Yearly activity ranges from 5 filings in 2024 to 11 in 2022. Stored 90-day results exist for 27 purchases (median minus 1.5%, 19% positive); they describe the past only.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
